• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

运用临床和放射组学特征预测肝细胞癌降期的结果。

Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features.

机构信息

Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.

Research Unit of Precision hepatobiliary Surgery Paradigm, Chinese Academy of Medical Sciences, Beijing, China.

出版信息

BMC Cancer. 2023 Sep 12;23(1):858. doi: 10.1186/s12885-023-11386-0.

DOI:10.1186/s12885-023-11386-0
PMID:37700255
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10496191/
Abstract

BACKGROUND

Downstaging of hepatocellular carcinoma (HCC) makes it possible for patients beyond the criteria to have the chance of liver transplantation (LT) and improved outcomes. Thus, a procedure to predict the prognosis of the treatment is an urgent requisite. The present study aimed to construct a comprehensive framework with clinical information and radiomics features to accurately predict the prognosis of downstaging treatment.

METHODS

Specifically, three-dimensional (3D) tumor segmentation from contrast-enhanced computed tomography (CT) is employed to extract spatial information of the lesions. Then, the radiomics features within the segmented region are calculated. Combining radiomics features and clinical data prompts the development of feature selection to enhance the robustness and generalizability of the model. Finally, we adopt the support vector machine (SVM) algorithm to establish a classification model for predicting HCC downstaging outcomes.

RESULTS

Herein, a comparative study was conducted on three different models: a radiomics features-based model (R model), a clinical features-based model (C model), and a joint radiomics clinical features-based model (R-C model). The average accuracy of the three models was 0.712, 0.792, and 0.844, and the average area under the receiver-operating characteristic (AUROC) of the three models was 0.775, 0.804, and 0.877, respectively.

CONCLUSIONS

The novel and practical R-C model accurately predicted the downstaging outcomes, which could be utilized to guide the HCC downstaging toward LT treatment.

摘要

背景

肝细胞癌(HCC)的降期使得超出标准的患者有机会接受肝移植(LT)并获得更好的治疗效果。因此,预测治疗预后的方法是当务之急。本研究旨在构建一个包含临床信息和放射组学特征的综合框架,以准确预测降期治疗的预后。

方法

具体来说,采用增强 CT 的三维(3D)肿瘤分割方法提取病变的空间信息。然后,计算分割区域内的放射组学特征。结合放射组学特征和临床数据,进行特征选择,以提高模型的稳健性和通用性。最后,采用支持向量机(SVM)算法建立预测 HCC 降期结果的分类模型。

结果

在此,对三种不同的模型进行了对比研究:基于放射组学特征的模型(R 模型)、基于临床特征的模型(C 模型)和基于放射组学联合临床特征的模型(R-C 模型)。三个模型的平均准确率分别为 0.712、0.792 和 0.844,三个模型的平均接收者操作特征曲线(AUROC)下面积分别为 0.775、0.804 和 0.877。

结论

新型实用的 R-C 模型能准确预测降期结果,可用于指导 HCC 降期至 LT 治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/81c85fbb5f5c/12885_2023_11386_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/425b8445d570/12885_2023_11386_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/d23498813f57/12885_2023_11386_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/a085c9032f47/12885_2023_11386_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/0bfcefac496c/12885_2023_11386_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/81c85fbb5f5c/12885_2023_11386_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/425b8445d570/12885_2023_11386_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/d23498813f57/12885_2023_11386_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/a085c9032f47/12885_2023_11386_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/0bfcefac496c/12885_2023_11386_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b134/10496191/81c85fbb5f5c/12885_2023_11386_Fig5_HTML.jpg

相似文献

1
Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features.运用临床和放射组学特征预测肝细胞癌降期的结果。
BMC Cancer. 2023 Sep 12;23(1):858. doi: 10.1186/s12885-023-11386-0.
2
CT radiomics based on different machine learning models for classifying gross tumor volume and normal liver tissue in hepatocellular carcinoma.基于不同机器学习模型的CT影像组学在肝细胞癌肿瘤总体积与正常肝组织分类中的应用
Cancer Imaging. 2024 Jan 26;24(1):20. doi: 10.1186/s40644-024-00652-4.
3
Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics.基于治疗前 CT 影像的影像组学模型预测接受经动脉化疗栓塞术治疗的肝细胞癌患者的生存情况。
AJR Am J Roentgenol. 2018 Nov;211(5):1026-1034. doi: 10.2214/AJR.18.19507. Epub 2018 Sep 21.
4
[Value of the application of enhanced CT radiomics and machine learning in preoperative prediction of microvascular invasion in hepatocellular carcinoma].[增强CT影像组学与机器学习在肝细胞癌微血管侵犯术前预测中的应用价值]
Zhonghua Yi Xue Za Zhi. 2021 May 11;101(17):1239-1245. doi: 10.3760/cma.j.cn112137-20200820-02425.
5
Prediction of early recurrence of hepatocellular carcinoma after liver transplantation based on computed tomography radiomics nomogram.基于 CT 影像组学列线图预测肝移植术后肝细胞癌早期复发
Hepatobiliary Pancreat Dis Int. 2022 Dec;21(6):543-550. doi: 10.1016/j.hbpd.2022.05.013. Epub 2022 Jun 1.
6
Preoperative prediction for pathological grade of hepatocellular carcinoma via machine learning-based radiomics.基于机器学习的放射组学术前预测肝细胞癌的病理分级。
Eur Radiol. 2020 Dec;30(12):6924-6932. doi: 10.1007/s00330-020-07056-5. Epub 2020 Jul 22.
7
Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.基于术前增强 CT 的影像组学模型预测肝细胞癌患者总生存期。
World J Gastroenterol. 2022 Aug 21;28(31):4376-4389. doi: 10.3748/wjg.v28.i31.4376.
8
Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma through dynamic contrast-enhanced magnetic resonance imaging-based radiomics.基于动态对比增强磁共振成像的放射组学术前预测巨梁型/块状型肝细胞癌。
World J Gastroenterol. 2023 Apr 7;29(13):2001-2014. doi: 10.3748/wjg.v29.i13.2001.
9
Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: A multi-institutional study.基于增强 CT 影像组学的机器学习分析预测肝癌切除术后复发:多中心研究。
EBioMedicine. 2019 Dec;50:156-165. doi: 10.1016/j.ebiom.2019.10.057. Epub 2019 Nov 15.
10
CT radiomics-based biomarkers can predict response to immunotherapy in hepatocellular carcinoma.基于 CT 影像组学的生物标志物可预测肝癌对免疫治疗的反应。
Sci Rep. 2024 Aug 28;14(1):20027. doi: 10.1038/s41598-024-70208-w.

引用本文的文献

1
Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study.经导管动脉化疗栓塞术(TACE)联合仑伐替尼和信迪利单抗治疗不可切除肝细胞癌的疗效、安全性和生物标志物分析:一项真实世界研究。
Cancer Immunol Immunother. 2024 Nov 5;74(1):13. doi: 10.1007/s00262-024-03857-5.
2
Systematic review and meta-analysis on the classification metrics of machine learning algorithm based radiomics in hepatocellular carcinoma diagnosis.基于机器学习算法的放射组学在肝细胞癌诊断中分类指标的系统评价与荟萃分析
Heliyon. 2024 Aug 14;10(16):e36313. doi: 10.1016/j.heliyon.2024.e36313. eCollection 2024 Aug 30.
3

本文引用的文献

1
The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.甲胎蛋白、甲胎蛋白异质体 3、脱γ-羧基凝血酶原在肝癌检测中的表现:美国的一项 3 期生物标志物研究。
Clin Gastroenterol Hepatol. 2023 Feb;21(2):415-423.e4. doi: 10.1016/j.cgh.2022.01.047. Epub 2022 Feb 3.
2
Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation.用于将肝癌桥接至肝移植及降期的局部区域治疗
Cancers (Basel). 2021 Nov 5;13(21):5558. doi: 10.3390/cancers13215558.
3
Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
Integrating Omics Data and AI for Cancer Diagnosis and Prognosis.
整合组学数据与人工智能用于癌症诊断和预后评估
Cancers (Basel). 2024 Jul 3;16(13):2448. doi: 10.3390/cancers16132448.
肝癌降期治疗的结果:来自多中心评估肝移植前肿瘤缩小(MERITS-LT)研究联盟的结果。
Gastroenterology. 2021 Nov;161(5):1502-1512. doi: 10.1053/j.gastro.2021.07.033. Epub 2021 Jul 28.
4
The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma.桥接或降期对肝细胞癌肝移植术后生存结局的实际影响。
Liver Cancer. 2020 Dec;9(6):721-733. doi: 10.1159/000507887. Epub 2020 Oct 28.
5
Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives.放射组学在预测非小细胞肺癌治疗反应中的应用:现状、挑战与未来展望。
Eur Radiol. 2021 Feb;31(2):1049-1058. doi: 10.1007/s00330-020-07141-9. Epub 2020 Aug 18.
6
Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies.肝细胞癌的局部区域治疗方法:最新进展与管理策略
Cancers (Basel). 2020 Jul 15;12(7):1914. doi: 10.3390/cancers12071914.
7
Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: A multicenter study from China.杭州标准作为肝移植前肝细胞癌的降期标准:来自中国的多中心研究。
Hepatobiliary Pancreat Dis Int. 2020 Aug;19(4):349-357. doi: 10.1016/j.hbpd.2020.06.011. Epub 2020 Jun 21.
8
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.肝癌肿瘤降期后行肝移植的研究(XXL):一项随机、对照、2b/3 期临床试验。
Lancet Oncol. 2020 Jul;21(7):947-956. doi: 10.1016/S1470-2045(20)30224-2.
9
A Radiomics Nomogram for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma.一种用于术前预测肝细胞癌微血管侵犯的影像组学列线图。
Liver Cancer. 2019 Oct;8(5):373-386. doi: 10.1159/000494099. Epub 2018 Nov 27.
10
A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.一种基于新 ALBI 模型预测巴塞罗那临床肝癌分期 B 期患者经肝动脉化疗栓塞治疗后的生存情况。
Liver Int. 2019 Sep;39(9):1704-1712. doi: 10.1111/liv.14194. Epub 2019 Jul 30.